BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of…
Monday, February 27th at 10am ETMADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code:…
NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S.…
Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of 2023BEDFORD, Mass. and SHANGHAI, China,…
LAKE FOREST, Ill., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty…
Live event scheduled for Friday, February 24th at 11:00 am Eastern TimeIRVINE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- AEON…
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data…
PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters…
DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative…
– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively…